Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Apyx Medical Corporation and Encourages Investors to Contact the Firm Before June 17

May 4, 2019

NEW YORK--(BUSINESS WIRE)--May 4, 2019--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of Florida on behalf of those who acquired Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX ) securities during the period from August 1, 2018 through April 1, 2019 (the “Class Period”). Investors have until June 17, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that Apyx failed to disclose to investors: (i) that the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (ii) that, as a result, the clinical study did not support the Company’s application for regulatory clearance; and (iii) that, as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing.

On April 1, 2019, Apyx announced that it had withdrawn its 510(k) application for Renuvion, a patented surgical device for use in dermal surgical procedures, citing concerns raised by the FDA. Apyx revealed that the FDA had questioned the device’s clinical results, which differed greatly from two of the investigational centers used in the study, as well as the potential impact of certain protocol deviations. On this news, shares of Apyx fell $2.49 per share, approximately 35.8%, to close at $4.46 on April 2, 2019.

If you acquired Apyx securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190504005003/en/

CONTACT: Kirby McInerney LLP

Thomas W. Elrod, Esq., (212) 371-6600





SOURCE: Kirby McInerney LL

Copyright Business Wire 2019.

PUB: 05/04/2019 11:30 AM/DISC: 05/04/2019 11:30 AM